AzTrials
AzTrials

Pulmonary HypertensionNCT07082400

Screening and Phenotyping of Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction .

A study testing right heart catheter in people with Pulmonary Hypertension, run by Sohag University.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Left-sided heart failure (HF) is known to cause pulmonary hypertension (PH), but the development and severity of PH in HF is highly variable, and contributing factors are not fully understood. Pulmonary hypertension (PH) due to left heart disease (PH-LHD) is a growing health problem with high morbidity and mortality . Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Pulmonary Hypertension
What is being tested?
right heart catheter
Type of treatment
Surgery or procedure
How many people
100 participants
Where
No sites listed yet
Study dates
1 Aug 2025to 1 Aug 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • All patients diagnosed with diastolic heart failure through The H2FPEF score and suspected pulmonary hypertension

Who cannot join

  • Heart Failure with reduced ejection fraction .
  • Severe lung diseases as a comborbid condition ,such as COPD (GOLD) class 4 , severe interstitial lung disease.
  • Chronic thromboembolic PH .

Trial locations and contacts

No sites are listed yet. Contact the study team or a site near you to ask about taking part.

Ahmed M Sayed, Assistant lecturer contact

+201095630589

ahmed_mahmoud4@med.sohag.edu.eg

Hamdy M Radwan, Professor contact

About this study

Left-sided heart failure (HF) is known to cause pulmonary hypertension (PH), but the development and severity of PH in HF is highly variable, and contributing factors are not fully understood. Pulmonary hypertension (PH) due to left heart disease (PH-LHD) is a growing health problem with high morbidity and mortality . PH-LHD is the most frequent subset of PH, resulting from left ventricular (LV) dysfunction (systolic and/or diastolic) and/or valvular heart disease (VHD) . Although initial studies focused on patients with reduced left ventricular ejection fraction (EF) , early isolated case reports and more recent case series have shown that PH can occur in heart failure with preserved ejection fraction (HFpEF). There is now growing appreciation that PH is common and may be severe in elderly patients with HFpEF . However, the true prevalence and severity of PH in HFpEF from the general community remain unknown. Previous studies were limited by selection bias, and population-based data have, to date, been lacking. Common to left ventricular failure regardless of EF, increased left-sided filling pressure leads to pulmonary venous hypertension (HTN) and post-capillary PH. In the presence of preserved systolic function, the development of pulmonary venous HTN is associated with the severity of left ventricular diastolic dysfunction, as has been shown in patients with aortic stenosis and normal EF. Beyond this post-capillary contribution to PH, a reactive increase in pulmonary arterial tone or intrinsic arterial remodeling can result in a superimposed pre-capillary component of pulmonary arterial HTN. This has been shown to occur in patients with mitral stenosis and HF with reduced EF. In HFpEF without valvular disease, however, the relative contributions of these pre- and post-capillary components to PH are unclear. Pulmonary arterial compliance (CPA) is a predictor of prognosis in patients with SHF, irrespective of pulmonary vascular resistance (PVR).Recently, at the fifth World Symposium on Pulmonary Hypertension in Nice, France, in 2013, two subsets of PH-LHD (post-capillary PH) were defined as isolated post-capillary PH (Ipc-PH; diastolic pulmonary vascular pressure gradient [DPG] < 7 mm Hg, previously labeled as "passive" PH-LHD) and combined pre- and post-capillary PH (Cpc-PH; DPG ≥ 7 mm Hg, previously labeled as "out-of-proportion" or "reactive" PH-LHD, because of pulmonary pressures higher than expected from increased pulmonary artery wedge pressure (PAWP). HF therapies such as β-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and spironolactone improve LV function and reduce LV filling pressures, but have not been convincingly shown to improve RV function in humans. In contrast, pulmonary vasodilators that have been approved for the treatment of pulmonary arterial hypertension (PAH) have never demonstrated a benefit in HF populations, including recent randomized trials . There are Diagnostic Dilemmas as diastolic heart failure causing pulmonary hypertension and pulmonary hypertension causing diastolic dysfunction. Chronic right ventricular pressure overload can affect left ventricular diastolic function in several ways. Left ventricular relaxation is under the triple control of load, myocardial properties, and the uniformity of load in space and time .18 In chronic right ventricular pressure overload, the load on the intraventricular septum is dramatically increased and as it hypertrophies, the myocardial properties of the septum are altered. The motion of the intraventricular septum in systole and diastole is asynchronous. All these factors could contribute to impairment in global left ventricular relaxation. In Doppler echocardiographic studies of IPAH, impaired relaxation with decreased E/A ratio and increased isovolumic relaxation time and deceleration time have been consistently reported . While patients must have normal PCWP to be diagnosed with IPAH, there is considerable evidence that chronic right ventricular pressure overload can cause reduced left ventricular compliance. The external forces affecting the LV-EDPVR include right ventricular pressure and pericardial pressure.19_20 The effect of right ventricular pressures on the LV-EDPVR is termed "ventricular interdependence" and is accentuated in the presence of an intact pericardium . These effects were also apparent in chronic right ventricular pressure overload, but a decrease in myocardial compliance (as assessed by the stress-strain relationship) was also seen.

Being tested
right heart catheter
Medical subject headings
Hypertension, Pulmonary

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • right heart catheterProcedure or surgery

    measurement of hemodynamics of pulmonary circulation in patients diagnosed with heart failure with preserved ejection fraction

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. mean pulmonary arterial pressure

    through right heart catheter

    Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Jul 2025
  2. Study start1 Aug 2025 (estimated)
  3. Primary completion1 Aug 2026 (estimated)
  4. Study completion1 Aug 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07082400
Sponsor's protocol ID
Soh-Med-25-6--3MD
Status last verified
Jul 2025
First submitted
16 Jul 2025
Last updated
24 Jul 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Maron BA, Bortman G, De Marco T, Huston JH, Lang IM, Rosenkranz SH, Vachiery JL, Tedford RJ. Pulmonary hypertension associated with left heart disease. Eur Respir J. 2024 Oct 31;64(4):2401344. doi: 10.1183/13993003.01344-2024. Print 2024 Oct.

    PubMed 39209478
  • Wissmuller M, Dohr J, Adler J, Ochs L, Tichelbacker T, Hohmann C, Baldus S, Rosenkranz S. Pulmonary hypertension associated with left heart disease. Herz. 2023 Aug;48(4):266-273. doi: 10.1007/s00059-023-05189-z. Epub 2023 Jun 8.

    PubMed 37289211
  • Madonna R, Biondi F, Ghelardoni S, D'Alleva A, Quarta S, Massaro M. Pulmonary hypertension associated to left heart disease: Phenotypes and treatment. Eur J Intern Med. 2024 Nov;129:1-15. doi: 10.1016/j.ejim.2024.07.030. Epub 2024 Aug 1.

    PubMed 39095300
  • Redfield MM, Borlaug BA. Heart Failure With Preserved Ejection Fraction: A Review. JAMA. 2023 Mar 14;329(10):827-838. doi: 10.1001/jama.2023.2020.

    PubMed 36917048

Questions about this trial

What is this clinical trial studying?

A study testing right heart catheter in people with Pulmonary Hypertension, run by Sohag University.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 24 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Ahmed M Sayed, Assistant lecturer (+201095630589, ahmed_mahmoud4@med.sohag.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

mean pulmonary arterial pressure (time frame: 1 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07082400, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jul 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in